Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023–2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach

Vaccine, Год журнала: 2025, Номер 49, С. 126808 - 126808

Опубликована: Янв. 30, 2025

Язык: Английский

---

Understanding COVID-19 Vaccine Hesitancy in the United States: A Systematic Review

Vaccines, Год журнала: 2024, Номер 12(7), С. 747 - 747

Опубликована: Июль 6, 2024

The COVID-19 pandemic has presented the importance of vaccination as a pivotal strategy for controlling its spread. However, vaccine hesitancy poses significant barrier to achieving widespread immunization in United States. This systematic review utilizes 5C model examine factors contributing hesitancy, which include confidence vaccines, complacency about disease risk, calculations individual benefit, convenience vaccination, and collective responsibility protection others. Methods: We conducted comprehensive search across several relevant databases gray literature, identifying 544 studies that used quantitative qualitative methods explore general U.S. population. Results: identifies complex interplay affecting such concerns over safety efficacy, misinformation conspiracy theories, demographic variables, socioeconomic conditions. Key strategies increasing uptake transparent effective communication along with proactive community engagement. Conclusions: To effectively mitigate it is crucial understand multifaceted causes. Tailored interventions consider cultural contexts prioritize clear communication, involvement, specific address unique can enhance acceptance.

Язык: Английский

---

Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections

Frontiers in Immunology, Год журнала: 2025, Номер 15

Опубликована: Янв. 21, 2025

Purpose Many individuals with inborn errors of immunity (IEIs) have poor humoral immune (HI) vaccine responses. Only a few studies examined specific cell-mediated (CMI) responses to coronavirus disease 2019 (COVID-19) vaccines in this population. Therefore, the purpose study was examine HI and CMI up 6 months post-COVID-19 dose 3 adults IEIs. Methods A multi-center prospective observational conducted across Canada collect severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-specific data at 4- 24-week intervals after doses 2 (D2 + 4wk/D2 24wk/D3 4wk/D3 24wk). Results total 149 IEIs 423 healthy controls were recruited from July 2021 October 2023. Geometric mean anti-spike IgG (binding antibody units/mL) spike-specific T-cell [IFN-γ T cells/10 peripheral blood mononuclear cells (PBMCs)] significantly lower compared D2 4wk, D3 24wk. However, completing primary series (three for two healthy), both IEI participants persisted comparable. There strong correlation between neutralizing titer (ID50) but not ID50 CMI. only one reported case hospitalized COVID-19 before none among participants. Conclusion Adults mounted following vaccines, which than those present least 3. These support initial recommendation three-dose

Язык: Английский

---

Adult vaccinations against respiratory infections

Expert Review of Anti-infective Therapy, Год журнала: 2025, Номер unknown

Опубликована: Янв. 23, 2025

Lower respiratory infections have a huge impact on global health, especially in older individuals, immunocompromised people, and those with chronic comorbidities. The COVID-19 pandemic highlights the importance of vaccination. However, there are lower rates vaccination adult population that commonly due to missed opportunity vaccinate. Vaccination offers best strategy prevent hospitalization, complications, death caused by infections. In this review, authors provide an overview vaccines for population. review available data about preventing infections, focusing pneumococcal vaccine, influenza vaccines, syncytial virus (RSV) vaccines. discuss currently scientific evidence role against Finally, current recommendations Scientific effectiveness is important. An efficient implementation immunization strategies will decrease burden Recognizing existing their essential achieve high rate

Язык: Английский

---

Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants

Viruses, Год журнала: 2025, Номер 17(2), С. 168 - 168

Опубликована: Янв. 25, 2025

As new SARS-CoV-2 variants continue to emerge, it is important evaluate the potency of antiviral drugs support their continued use. Remdesivir (RDV; VEKLURY®) an approved treatment for COVID-19, and obeldesivir (ODV) are inhibitors RNA-dependent RNA polymerase Nsp12. Here we show these two compounds retain activity against Omicron BA.2.86, BF.7, BQ.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, JN.1.7, JN.1.18, KP.2, KP.3, LB.1, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, XBF when compared with reference strains. Genomic analysis identified 29 Nsp12 polymorphisms in previous variants. Phenotypic confirmed no impact on RDV or ODV suggests containing remain susceptible both compounds. These data use context circulating development as therapeutic.

Язык: Английский

---

Neutralizing antibody responses to three XBB protein vaccines in older adults

Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)

Опубликована: Фев. 2, 2025

Язык: Английский

---

Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection

Human Vaccines & Immunotherapeutics, Год журнала: 2025, Номер 21(1)

Опубликована: Март 7, 2025

The coronavirus disease (COVID-19) pandemic accelerated development of various vaccine platforms. Among them, mRNA vaccines played a crucial role in controlling the due to their swift and efficacy against virus variants. Despite success these vaccines, recent studies highlight challenges evaluating efficacy, especially individuals with prior COVID-19 infection. Weakened neutralizing antibody responses after additional doses are observed populations, raising concerns about using titers as sole immune correlate protection. While antibodies remain primary endpoint immunogenicity trials, they may not fully capture response populations widespread infection or vaccination. This review explores reduced previously infected individuals, impact on evaluation. It also offers recommendations for improving assessment, stressing incorporation markers such cell-mediated immunity enable more comprehensive understanding vaccine-induced immunity.

Язык: Английский

---

What Is Next for COVID-19 Vaccination?

Seminars in Respiratory and Critical Care Medicine, Год журнала: 2025, Номер unknown

Опубликована: Март 31, 2025

Abstract Whenever a new COVID-19 vaccination season starts, we must face challenges, including which vaccines to use, the update of high-risk groups be vaccinated, and especially type amount information communicated people in order promote vaccination. recommendations should fit these specific conditions. The use effective against predominant SARS-CoV-2 virus variants extent immune response (waning immunity) are key aspects try protect better populations. Updated currently swiftly available. However, number vaccinated with any additional booster dose is declining. Improved health training for care professionals, together tools make simpler recommendations, can encourage higher rates. Addressing challenges essential improve coverage ensure adequate protection evolving threats. has become constant presence our society. changes but neither endemic nor seasonal so far. Omicron variant prevailed nearly 2 years now several its subvariants like JN.1, KP.2, or XEC dominant ones. In this moving situation, main message same: safe effective. role current efforts mitigate severity disease reduce risk complications death, instead preventing most infections. New at different stages clinical research.

Язык: Английский

---

Effectiveness of 2023–2024 COVID-19 vaccines against COVID-19–associated hospitalizations among adults aged ≥18 years with end stage kidney disease — United States, September 2023–April 2024

Vaccine, Год журнала: 2025, Номер 55, С. 127010 - 127010

Опубликована: Апрель 5, 2025

Язык: Английский

---

Optimal Timing of Vaccination: A Narrative Review of Integrating Strategies for COVID-19, Influenza, and Respiratory Syncytial Virus

Infectious Diseases and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Апрель 9, 2025

Lower respiratory tract infections caused by SARS-CoV-2, influenza, and syncytial virus (RSV) cause a significant disease burden globally, despite the availability of effective vaccines. Certain populations, such as older adults (≥ 60 years) individuals all ages with particular comorbidities, are at increased risk for severe outcomes, including hospitalization death. National administration schedules available vaccines against viruses not unified, current guidelines clear directive, concerning optimal timing vaccination. Herein, we formulate an evidence-based position regarding COVID-19, RSV vaccination chronic based on synthesis literature guidelines. Vaccination impact were found to be influenced vaccinee factors, age waning vaccine effectiveness seasonal pathogen burden. Because display unique patterns within between regions, local epidemiological surveillance each is crucial determining To maximize benefits these vaccines, peak period greatest outcomes should aligned. Thus, other recommended given ahead start season (or regionally appropriate time) co-administered single, routine visit represent approach protecting at-risk populations. More data will required establish clinical benefit additional doses whether may integrated schedule. Coordinated policy decisions that align strain selection new annually reformulated would enable timely raising public health awareness, ultimately leading enhanced uptake. Implementation strategies require engagement healthcare providers strong, recommendations schedules.

Язык: Английский

---